Upfront Immunotherapy for Metastatic Kidney Cancer
0 Visualizzazioni
• 06/26/23
0
0
Incorporare
administrator
Iscritti
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti